Sanofi (SNY) said it anticipates that the review process for the ongoing U.S. regulatory review of tolebrutinib in non-relapsing secondary progressive multiple sclerosis will extend beyond the previously communicated U.S. target action date of December 28, 2025, and expects further guidance from the FDA by the end of the first quarter of 2026. In response to an FDA request, Sanofi has submitted an expanded access protocol for tolebrutinib in nrSPMS, underscoring the company’s commitment to providing eligible patients with access to this investigational therapy. Sanofi strongly believes in the risk-benefit profile of tolebrutinib for the treatment of nrSPMS.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Sanofi: Buy Rating Maintained Amid Attractive Valuation and Long-Term Growth Potential Despite Pipeline Setbacks
- Sanofi Expands Vaccine Portfolio and Gains China Approval for Rare Disease Drugs
- Sanofi says Qfitlia, Cablivi approved in China for rare hematologic diseases
- Sanofi price target lowered to EUR 100 from EUR 102 at HSBC
- Guggenheim downgrades Sanofi on lack of near-term pipeline catalysts